Pfizer Inc. Revenue in 2024

Pfizer Inc. reported $63.6B in revenue for fiscal year 2024. This represents a growth of 8.7% compared to the 2023 figure of $58.5B.

Pfizer's revenue in 2021 was $81.3 billion. In 2022 it was $100.3 billion — the COVID vaccine and Paxlovid antiviral together added roughly $57 billion in revenue in their peak year. In 2023, as vaccine demand normalized and governments stopped stockpiling antivirals, revenue fell to $58.5 billion. By 2024 it had recovered to $63.6 billion. These four data points describe a company whose underlying business is growing, distorted by an extraordinary windfall and its subsequent normalization. Net income of $8.0 billion in 2024 sits against a market capitalization of $148 billion — a price-to-earnings ratio that reflects both the earnings recovery from the 2023 decline and investor uncertainty about the patent cliff ahead. Key drugs in the portfolio face generic competition over the next five to seven years, a structural challenge that every large pharmaceutical company manages through pipeline investment and acquisitions. The $43 billion Seagen acquisition completed in 2023 was the largest deployment of COVID-era capital. Seagen's antibody-drug conjugate technology — engineered molecules that deliver chemotherapy directly to cancer cells — represents a platform Pfizer management believes will generate multiple blockbuster drugs. The financial case requires those drugs to actually reach market and achieve commercial adoption, a process measured in years. Pfizer's founding investment of $2,500 in 1849 grew into the company that produced the first major mRNA vaccine at commercial scale in 2021. The $90,000 equivalent starting capital and the $148 billion current market cap represent 175 years of compounding through exactly the reinvestment-in-discovery cycle that has characterized every major pharmaceutical innovator. The question is whether that cycle continues to generate the next Lipitor, the next Paxlovid — or whether the patent expirations ahead will require the next defining acquisition to maintain the revenue trajectory.